Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, has reported positive interim safety and efficacy results from its Phase 2 trial of ENV105 in combination with apalutamide for advanced metastatic prostate cancer. The findings, presented at the European Society for Medical Oncologists Meeting, indicate a clinical benefit in 86% of treated patients, with durable progression-free survival and no dose-limiting toxicities. These results suggest that ENV105 may extend the effectiveness of standard care while maintaining strong tolerability.
The company's CEO, John Yu, M.D., highlighted these milestones in a Letter to Shareholders, outlining 2025 accomplishments and the outlook for 2026. ENV105 is an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. Elevated CD105 levels in response to standard therapy often lead to resistance and disease relapse. By targeting CD105, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
Kairos Pharma continues patient recruitment for the Phase 2 trial, with enrollment expected to reach 100 across leading U.S. cancer centers. The company is also conducting a Phase 1 trial for lung cancer, addressing significant unmet medical needs. Based in Los Angeles, California, Kairos Pharma utilizes structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV105, is central to its strategy of enhancing the efficacy of existing treatments.
For more details on the press release, visit https://ibn.fm/YDPft. Investors seeking the latest news and updates on Kairos Pharma can access the company's newsroom at https://ibn.fm/KAPA.
